Winship Study Drives FDA Approval for New Leukemia Therapy
December 17, 2024
December 17, 2024
ATLANTA, Georgia, Dec. 17 (TNSres) -- Emory University Winship Cancer Institute issued the following news release:
The U.S. Food and Drug Administration (FDA) has approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.) for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a fast-growing blood cancer that starts in the bone marrow and affects the body's ability to fight infection. The approval follows results of a landmark study, published in T . . .
The U.S. Food and Drug Administration (FDA) has approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.) for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), a fast-growing blood cancer that starts in the bone marrow and affects the body's ability to fight infection. The approval follows results of a landmark study, published in T . . .